reltecimod Report issue

Biologics Peptide Experimental
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)O)C(C)C
  • InChIKey: VRNHFZYMPDKTBS-WYUJEMNCSA-N
  • Mol. Mass: 1037.2
  • ALogP: Missing data
  • ChEMBL Molecule:
    reltecimod  
More Chemistry

Pharmacology

Alternative names

ab103

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Acute Kidney Injury (Phase 2)

Fasciitis, Necrotizing (Phase 3)

Fournier Gangrene (Phase 3)

Healthy Volunteers (Phase 1)

Peritonitis (Phase 2)

Soft Tissue Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue